iRhythm Technologies, Inc. (NASDAQ: IRTC) is a Healthcare company (Medical - Devices) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
iRhythm Technologies, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $89.67, iRhythm Technologies, Inc. trades at 3.5x sales and 17.0x book value, with an EV/EBITDA of 3621.1. Over the last twelve months it generated about $844M of revenue and a net loss of $38M. It runs a gross margin of 72.3%, an operating margin of -4.5% and a net margin of -4.5%. It shows return on equity of -22.8%, return on invested capital of -4.2% and a free cash flow yield of 0.2%. On the balance sheet: a debt-to-equity ratio of 4.10 and a current ratio of 3.57. Over the past 52 weeks the share price ranged from $82.85 to $192.47, with a beta of 1.40.
iRhythm Technologies, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 19 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, iRhythm Technologies, Inc. (IRTC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.0% / 30% · Interest income / Revenue 2.12% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 17.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.0% / 33% · Receivables / Mkt Cap (36m) 2.18% / 49% · Interest income / Revenue 2.12% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 17.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.0% / 33.33% · Receivables / Mkt Cap (24m) 2.18% / 33.33% · Interest income / Revenue 2.12% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 61.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 54.3% / 33.33% · Receivables / Avg Assets (4Q) 7.65% / 33.33% · Interest income / Revenue 2.12% / 5% | Fail |
| FTSE | Debt / Total Assets 59.7% / 33.33% · (Cash+ST Inv) / Total Assets 51.4% / 33.33% · (Cash+Recv) / Total Assets 58.8% / 33.33% · Interest income / Revenue 2.12% / 5% | Fail |
It depends on the standard you follow. As of September 2026, iRhythm Technologies, Inc. (IRTC) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. iRhythm Technologies, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.12% of each dividend: iRhythm Technologies, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.